^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) + fulvestrant (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer
Published date:
05/20/2023
Excerpt:
This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC)….Median progression-free survival (PFS) was 8 weeks (95% CI: 2–52)….At week 24, 7 (25.0%) (95% CI: 10.7–44.9) participants had stable disease...
DOI:
10.1038/s41523-023-00544-z
Trial ID:
